Search results
Results From The WOW.Com Content Network
CD20 is a CD marker—a molecule on the cell surface that can be used to identify and type a particular cell in the body. CD20 is found on the surface of B cells, but let's back up and make this easier to understand.
CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
CD20 (cluster of differentiation 20) is a protein that is expressed on the surface of B cells, starting at the pre-B cell stage and on mature B cells in the bone marrow and in the periphery.
Results: Both CD19 and CD20 were highly expressed on CD20 treatment naïve tumor cells, with a slightly higher median percentage of positive tumor cells for CD19 (98%) compared with CD20 (93%) (p=0.003), and one case lacking CD20 expression. When compared with background benign B-cells, CD20 was frequently overexpressed on tumor cells (mean MFR ...
Here, we demonstrate that CD20 controls the nanoscale organization of receptors on the surface of resting B lymphocytes. CRISPR/Cas9-mediated ablation of CD20 in resting B cells resulted in relocalization and interaction of the IgM-class B cell antigen receptor with the coreceptor CD19.
Originally conceived as a method of eliminating cancerous B cells, BCDTs such as those targeting CD20, CD19 and BAFF are now used to treat autoimmune diseases, including systemic lupus...
Several small molecules (such as histone deacetylase inhibitors, DNA methyl-transferase inhibitors, aurora kinase A/B inhibitors, farnesyltransferase inhibitors, FOXO1 inhibitors, and bryostatin-1) are being tested to upregulate cell-surface CD20 levels and increase the efficacy of anti-CD20 monoclonal antibodies.
CD20 encodes a B-cell membrane–spanning molecule important in B-cell proliferation and differentiation. It is expressed from early pre-B until mature B-cell stage but is lost on differentiation to plasma cell.
An incisional biopsy reveals a diffuse large B-cell lymphoma, and immunohistochemical staining is positive for the B-cell antigen CD20. The patient is referred to an oncologist. A...
The loss of CD20 on human B cells results in a dissolution of the IgD-class nanocluster and a transient B cell activation inducing a B cell-to-PC differentiation. Thus, CD20 is an essential gatekeeper of a membrane nanodomain and the resting state of naive B cells.